OncoMatch/Clinical Trials/NCT06038578
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Is NCT06038578 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TRK-950 and Ramucirumab for gastric adenocarcinoma.
Treatment: TRK-950 · Ramucirumab · Paclitaxel — This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: CAPRIN1 overexpression (≥30% at ≥2+ staining)
Tumor tissue must be evaluable for CAPRIN-1 staining at a CLIA certified laboratory and meet or exceed the cutoff value (30% at ≥ 2+ staining) as defined in the expression level requirements.
Excluded: HER2 (ERBB2) overexpression
HER2 positive gastric or GEJ adenocarcinoma [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received:
Documented objective radiographic or clinical disease progression ... during or after treatment. The prior treatment must meet one of the following criteria with the following treatment history: [see protocol for details]
Cannot have received: (ramucirumab, paclitaxel)
Prior history of treatment with ramucirumab or paclitaxel.
Lab requirements
Blood counts
Adequate organ function from specimens collected within 14 days prior to Day 1.
Kidney function
Adequate organ function from specimens collected within 14 days prior to Day 1.
Liver function
Adequate organ function from specimens collected within 14 days prior to Day 1.
Cardiac function
Baseline corrected QT (QTc) interval of > 470 msec for females and > 450 msec for males calculated using Fridericia's formula [excluded]. NYHA Class II-IV symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia [excluded].
Adequate organ function from specimens collected within 14 days prior to Day 1. Baseline corrected QT (QTc) interval of > 470 msec for females and > 450 msec for males calculated using Fridericia's formula [excluded]. NYHA Class II-IV symptomatic congestive heart failure, or symptomatic or poorly controlled cardiac arrhythmia [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- City of Hope at Orange County Lennar Foundation Cancer Center · Irvine, California
- University of California, Los Angeles · Santa Monica, California
- Texas Oncology Arlington North · Arlington, Texas
- Texas Oncology Bedford · Bedford, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06038578 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior disqualifies patients from enrollment.
Does this trial require CAPRIN1?
Yes, CAPRIN1 overexpression is a required biomarker for enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages